comparemela.com

Latest Breaking News On - Symphion tissue removal system - Page 2 : comparemela.com

Minerva Surgical (NASDAQ:UTRS) Hits New 1-Year Low at $2 77

Minerva Surgical, Inc. (NASDAQ:UTRS – Get Free Report)’s stock price hit a new 52-week low on Monday . The company traded as low as $2.77 and last traded at $2.89, with a volume of 10521 shares traded. The stock had previously closed at $3.29. Minerva Surgical Stock Performance The stock has a market cap of […]

Minerva Surgical (NASDAQ:UTRS) Shares Set to Reverse Split on Monday, October 2nd

Minerva Surgical, Inc. (NASDAQ:UTRS – Free Report)’s stock is going to reverse split on Monday, October 2nd. The 1-20 reverse split was announced on Monday, October 2nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 2nd. Minerva Surgical Stock Performance Minerva Surgical stock remained flat at […]

Minerva Surgical (NASDAQ:UTRS) Shares Scheduled to Reverse Split on Monday, October 2nd

Minerva Surgical, Inc. (NASDAQ:UTRS – Free Report) shares are set to reverse split before the market opens on Monday, October 2nd. The 1-20 reverse split was announced on Monday, October 2nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 2nd. Minerva Surgical Price Performance NASDAQ UTRS […]

Minerva Surgical (NASDAQ:UTRS) Shares Down 5 2%

Shares of Minerva Surgical, Inc. (NASDAQ:UTRS – Get Free Report) were down 5.2% during trading on Wednesday . The company traded as low as $0.20 and last traded at $0.20. Approximately 105,795 shares traded hands during trading, a decline of 95% from the average daily volume of 2,118,215 shares. The stock had previously closed at […]

Head to Head Survey: Minerva Surgical (NASDAQ:UTRS) & West Pharmaceutical Services (NYSE:WST)

Minerva Surgical (NASDAQ:UTRS – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Insider and Institutional Ownership 89.6% of Minerva […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.